40+ results for "IoT"
IoT Sensors Market to Reach USD 70.12 Billion by 2029, Growing at 34.4% CAGR, Says MarketsandMarkets™
Delray Beach, FL, Sept. 17, 2026 (GLOBE NEWSWIRE) -- The global IoT Sensors Market was valued at USD 16.02 billion in 2024 and is projected to grow from USD 20.68 billion in 2025 to USD 70.12 billion by 2029, at a CAGR of 34.4% during the forecast period, according to a report by MarketsandMarkets™. This robust growth is driven by increasing demand for connected and wearable devices, advancements in sensor technologies, and the prevalence of IPv6 adoption, with the introduction of 3GPP Release 1
Matisse Pharmaceuticals closed Series A financing round to advance isupartob sodium through phase 2 clinical development
Geleen, September 17, 2026 Matisse Pharmaceuticals B.V., a clinical stage company developing isupartob sodium for the treatment of sepsis, today announced the successful completion of its Series A financing round. The €14 million financing round was led by the company's existing & new shareholder base. This included participation from a group of institutional investors which included Brightlands Venture Partners & LIOF, private investors and management, further strengthening Matisse's long-term
Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center
BOSTON, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the signing of a Memorandum of Understanding (MOU) with the King Abdullah International Medical Research Center (KAIMRC) of King Saud bin Abdulaziz University for Health Sciences (KSAU-HS)
1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson's Disease Candidate ‘1ST-104’
Deal valued at up to $314.8 million, including milestones, with a separate $2.2 million strategic equity investment Collaboration leverages 1STBIO’s Type 2 LRRK2/c-Abl dual inhibitor to advance next-generation Parkinson's treatment YONGIN, South Korea, September 17, 2026 — 1ST Biotherapeutics, Inc. (“1STBIO”) and SK Biopharmaceuticals Co., Ltd. (“SKBP”) today announced that they have entered into an exclusive global licensing agreement and strategic equity investment (SI) partnership to advance
Blue Mountain and Stormbit Announce Strategic Partnership to Bring Asset Intelligence to the Point of Use for Life Sciences Manufacturers
STATE COLLEGE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Blue Mountain, the leader in GMP-compliant Enterprise Asset Management (EAM) software for Life Sciences, and Stormbit GmbH, part of the Systec & Solutions Group, today announced a strategic partnership to bring real-time asset intelligence directly to operators at the point of work in life sciences manufacturing environments. The partnership will connect Blue Mountain’s enterprise asset intelligence solution RAM with Stormbit’s VEYA digital
NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results
CEO Amir Heshmatpour has purchased 111,000 shares for approximately $418,700 since the Company announced positive NEO100 Phase 2a results CALABASAS, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that Executive Chairman, President and Chief Executive Officer Amir F. Heshmatpour purcha
Edge AIoT Chipset Revenue to More Than Triple by 2031 as Rising Cloud Costs Accelerate Local AI Adoption
New ABI Research findings show gateways and on-premises edge servers will lead growth as organizations seek lower OPEX, stronger resilience, and support for physical AI applications NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- The global edge AIoT chipset market reached US$32.7 billion in 2025 and is expected to more than triple by 2031, according to global technology intelligence firm ABI Research . The firm finds that edge gateways and on-premises edge servers will be the leading growth engine
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The antiviral market is entering a period where the need for new treatments is becoming impossible to ignore. Viral outbreaks can emerge quickly, cross borders and overwhelm healthcare systems before effective therapies are ready. That creates a lar
Clene Announces $4 Million Registered Direct Offering
Investment led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders $4 million registered direct offering priced at market under Nasdaq rules Proceeds are expected to be sufficient to fund the Company to mid-first quarter 2027 SALT LAKE CITY, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on ALS, today announced the prici
Avaí Bio and Austrianova Complete Adventitious Agent Testing of Master Cell Bank, Establish Working Cell Bank for α-Klotho Anti-Aging Therapy
LAS VEGAS, NV, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced, together with its joint venture partner and global biotechnology company Austrianova, the successful completion of comprehensive adventitious agent and viral testing of its GMP Master Cell Bank (MCB), from which its Working Cell Bank (WCB) was
Diasome Pharmaceuticals Strengthens Leadership Team as Company Prepares for Phase 3 Development
Sangeeta Sawhney, M.D Chief Medical Officer of Diasome Therapeutics Linda Rubinstein Chief Financial Officer of Diasome Therapeutics Experienced pharmaceutical R&D leader Sangeeta Sawhney, M.D., appointed Chief Medical Officer to lead clinical development as Diasome advances HDV-Insulin toward Phase 3 Paul Strumph, M.D., transitions to Senior Medical Advisor Linda Rubinstein appointed Chief Financial Officer; Health Business Group executives join senior management team to support strategy, busin
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
Experienced biopharmaceutical and nephrology leader joins SCYNEXIS to advance its rare disease development programs JERSEY CITY, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Todd Minga, M.D. as Senior Vice President, Research & Development, effective September 14, 2026. Dr. Minga brings more than two d
Orvida Pharma Announces Interim Financing Led by Recordati to Advance Ontivatrep Development for Rare Genetic Skin Diseases
Proceeds to support continued clinical development of ontivatrep, an oral TRPV3 inhibitor, with Phase 1b topline results in Olmsted syndrome expected by the end of 2026 NESS ZIONA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Orvida Pharma , a clinical-stage biotechnology company developing first- and best-in-class treatments for rare and severe genetic skin diseases, today announced the completion of an interim financing led by Recordati, a global pharmaceutical group headquartered in Milan, Ital
Axiom Biosciences Expands Manufacturing and Clinical Development Capabilities Through Partnership with GeneFab
Strategic CDMO collaboration strengthens Axiom’s development infrastructure as the company prepares to advance its therapeutic pipeline. SAN DIEGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Axiom Biosciences , a clinical-stage biotechnology company developing next-generation regenerative therapies and targeted biologics, today announced a strategic partnership with GeneFab, a cell and gene therapy contract development and manufacturing organization (CDMO), to support the continued advancement of Axiom’
Rare Twin Pregnancy with Eight Umbilical Cord Knots Successfully Managed at Rainbow Hospital, HRBR Layout, Bangalore
BENGALURU, India , Sept. 16, 2026 -- Rainbow Hospital, HRBR, has successfully managed one of the rare and complex forms of twin pregnancy Monochorionic Monoamniotic (MCMA) twins resulting in the safe delivery and recovery of two healthy baby girls. The case involved a 37-year-old woman with a history of primary infertility, who sought fertility treatment after several years of unsuccessful attempts to conceive. Following a comprehensive fertility evaluation and an individualised treatment plan, she successfully conceived MCMA twins under the care of Dr. Manju B Nair, Clinical Director Fertility Services.
Hummingbird Bioscience Appoints Dr. James Garner as President
Experienced life sciences executive brings more than two decades of global drug development, commercialization and business development experience SINGAPORE, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Hummingbird Bioscience (“Hummingbird”), a biotherapeutics company discovering and developing transformative medicines for diseases with significant unmet need, today announced the appointment of Dr. James Garner as President. Dr. Garner will join Hummingbird Bioscience’s leadership team and work alongside
Operational Technology (OT) Security Market Projected to Hit $178.93 Billion by 2035 | SNS Insider
The U.S. OT Security Market is projected to grow from $12.77 billion in 2025 to $50.46 billion by 2035, while Europe is expected to expand from $12.86 billion to $49.37 billion, driven by rising cyberattacks on critical infrastructure, IT–OT convergence, smart manufacturing, industrial IoT adoption, and strengthening cybersecurity requirements. Austin, United States, Sept. 15, 2026 (GLOBE NEWSWIRE) -- The Operational Technology (OT) Security Market was valued at USD 44.34 Billion in 2025 and is
Cavli Wireless to Launch AQ62 5G Autograde & CQM211 5G NR Modules at electronica India 2026
BENGALURU, India , Sept. 15, 2026 -- Cavli Wireless is set to launch the AQ62 5G Autograde and CQM211 5G NR modules at electronica India 2026 from September 16 18 at Hall H5 Booth F95, BIEC, Bengaluru. The two launches expand Cavli s 5G portfolio across automotive and high-performance IoT applications, addressing the growing demand for advanced cellular connectivity, edge processing, and scalable connected systems. The CQM211 5G NR module delivers multi-gigabit 5G connectivity and provides flexible integration options for new and existing hardware platforms. Designed for high-bandwidth applications, it is well suited for Industry 4.0 equipment, smart surveillance systems, routers, gateways, mobile Wi-Fi, and other edge applications requiring reliable high-speed connectivity.
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today announced the initial closing (the “Initial Closing”) of the Company’s Private Investment in Public Equity (“PIPE”) transaction. The round was led by
Bio Usawa and Axmed Partner to Expand Access to Affordable Biologic Medicines Across Africa
Strategic collaboration combines African biologics capabilities with technology-enabled procurement, with an initial focus on retinal diseases KIGALI, Rwanda and BASEL, Switzerland, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Bio Usawa and Axmed have entered into a strategic collaboration to expand patient access to advanced, affordable biologic medicines across African health systems. The collaboration brings together Bio Usawa’s capability to develop and manufacture high-quality biologics, including mo
SUNMI Deepens Eurasia Partnership at the Belt and Road Summit
HONG KONG , Sept. 13, 2026 -- SUNMI Technology (06810.HK) announced on September 10, separate cooperation agreements with T rkiye-based fintech company TOKEN and Mongolia-based digital bank M bank at the 11th Belt and Road Summit in Hong Kong. The agreements will bring together SUNMI s commercial IoT and digital commerce capabilities with the partners local expertise, advancing collaboration across digital commerce, smart devices, payments, and digital financial services.
Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs
NeOnc reports Phase 2a brain cancer data as BriaCell and Oncolytics advance breast and colorectal cancer studies DENVER, Sept. 11, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Recent cancer treatment advances span new FDA approvals and ongoing Phase 2 and Phase 3 clinical programs. NeOnc Technologies Holdings (NASDAQ: NTHI), BriaCell Therapeutics (NASDAQ: BCTX) and Oncolytics Biotech (NASDAQ: ONCY) have reported clinical and regulatory developments across brain, breast and colorectal cancer, a
Functional Food Ingredients Market
The next margin opportunity may already be inside the formulation: multifunctional ingredients can replace multiple inputs while improving performance, positioning and economics. Wilmington, DE, United States, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Functional Food Ingredients Market Emerging as one of the most Strategically Controlled Layers of Modern Nutrition The conversation about what goes into food has shifted. Consumers no longer ask only whether a product tastes good or costs less. They ask w
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
Amended terms of agreement include a transition to an integrated asset and technology partnership. SAN DIEGO and SUZHOU, China, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced that Third Arc Bio, Inc. (“Third Arc Bio”) selected the first lead candidate under the amended strategic licensing agreement. The agreement was est
Cannara Expands Financing to an $80 Million Syndicated Credit Facility with BMO and TD Bank, Further Strengthening Its Financial Foundation for Continued Growth
The new financing structure provides greater financial flexibility through an expanded $40 million revolving credit facility, reduced borrowing costs and an extended maturity to December 31, 2029 MONTREAL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, the “ Company ”, “ us ” or “ we ”) ( TSX: LOVE ) ( OTCQX: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis products at affordable prices with two mega facilities in Québec spanning over 1,600
Burning Rock Reports Second Quarter 2026 Financial Results
GUANGZHOU, China, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2026. Recent Business Updates Therapy Selection & MRD OncoScreen® BCMatch Tissue Kit has officially entered the Priority Review Channel of the Center for Medical Device Evaluation (
Iridium, Deutsche Telekom IoT, and Toyota Demonstrate Voice Messaging over Satellite via Iridium NTN Direct
Newly completed roaming agreement extends Deutsche Telekom s IoT coverage onto Iridium s satellite network MCLEAN, Va. , Sept. 10, 2026 -- Iridium Communications Inc. (Nasdaq: IRDM), a leading provider of global voice, data, aircraft surveillance, and positioning, navigation, and timing (PNT) satellite services, and Deutsche Telekom IoT (DT IoT) today announced the successful transmission of a voice message over Iridium NTN Direct in a demonstration with Toyota. The milestone message was sent from a Toyota vehicle equipped with a Nordic Semiconductor nRF9151 development board, a Deutsche Telekom IoT SIM and transmitted entirely via the Iridium satellite network during the Telekom Satellite Day 2026. The demonstration follows the successful completion of technical integration and a global roaming agreement between Iridium and Deutsche Telekom IoT.
CONNECTA Therapeutics Announces Financing to Advance Clinical Development of Fragile X Syndrome Program
€3.1 million financing led by new investor Clave Capital, with participation from existing investors Proceeds will support completion of ongoing Phase IIa trial of CTH120 in Fragile X syndrome, with topline data readout expected in mid-2027 BARCELONA, Spain, Sept. 10, 2026 (GLOBE NEWSWIRE) -- CONNECTA Therapeutics, a clinical-stage biotech company pioneering first-in-class neuroplasticity modulators to address unmet medical needs in central nervous system (CNS) disorders, today announced that it
Trinity Biotech’s Trinovium Subsidiary Signs Contract to Supply Red Team Investments with Advanced Liquid Cooling Solutions for AI Data Center Infrastructure
Trinovium to supply RTI with advanced fluids and analytical systems for deployment in a U.S. commercial pilot focused on AI and high-performance computing data center infrastructure Data center power densities are increasing rapidly as AI workloads expand, creating greater thermal-management demands and interest in advanced liquid cooling solutions DUBLIN and WILSONVILLE, Ore., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company, today
NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors
CALABASAS, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it has entered into definitive securities purchase agreements with new and existing healthcare focused institutional investors for the purchase and sale of 3,571,430 shares of the Company’s common stock (or pre-funded warr
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind’s Technosphere ® inhalation technology MannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a biopharmaceutical company focused on developing innovative,
Athernal Bio Secures Innovate UK Grant to Advance Cancer Interception in High-Risk Leukaemia
Innovate UK grant supports Athernal’s mission to intercept high-risk leukaemia before cancer develops Funding reflects growing confidence in cancer interception as an emerging therapeutic approach London, UK, September 9, 2026 – Athernal Bio , a UK biotechnology company pioneering cancer interception, today announced it has been awarded a grant of nearly £700,000 through Innovate UK’s Growth Catalyst - Investor Partnerships programme. The non-dilutive funding will accelerate the development of A
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated Cash and Cash Equivalents of $122.8 Million as of June 30, 2026, or $527.3 Million After Giving Effect to Braveheart Bio's Initial Public Offering, Expected to Support Advancement of BHB-1893 Through Late-Stage Clinical Development SAN FRANCISCO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutic
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes – – Cash runway remains projected into 2029, including the first $75 million collaboration extension fee from Gilead payable in Q4 2026 – SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced it
Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick
A look at the three approaches competing to help beta cell replacement survive the immune system Issued on behalf of AVAI Bio, Inc. LAS VEGAS, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - Type 1 diabetes has an unusual property among serious diseases: the science of curing it is largely solved. Put working insulin-producing beta cells back into a person, and their body will begin to regulate glucose again. That is not a hypothesis anymore. It has been demonstrated in huma
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
Agreement includes pre-payment commitments for product sales and distribution of the second-generation multi-cytokine-based HCW11-006 for use as a reagent Akron is a leading supplier of critical ancillary materials and accessory molecules for clinical and commercial scale-up of cell, gene and regenerative therapy products HCW Biologics supplies research and cGMP-grade HCW11-006 and Akron markets and distributes the reagent to its established network of research institutions and commercial compan
Sparrow Pharmaceuticals Appoints George Eldridge as Chief Financial Officer
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals , a targeted cardiometabolic therapeutics company, today announced the appointment of George Eldridge as Chief Financial Officer. Mr. Eldridge brings more than two decades of biotechnology financial leadership, including experience guiding multiple companies through successful initial public offerings. “We are thrilled to welcome George to Sparrow at such an important time for our company,” said Robert Jacks, President & Chief Ex
Merakris Therapeutics Launches Patent-Pending AmnioSurge™ With 360 Medical, Opening New Surgical Revenue Channel
Procedure-specific biologic technology combines surgeon training, scalable tissue processing and a capital-efficient commercialization model RESEARCH TRIANGLE PARK, N.C., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Merakris Therapeutics, a regenerative medicine company developing biologically derived therapeutics and medical technologies, today announced the commercial launch of AmnioSurge™ Amniotic Anastomosis Support Graft (ASG), a sterile, full-thickness amnion/chorion allograft featuring a patent-pen
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks
Dr. Soon-Shiong will Join PDS Biotech’s Board of Directors PDS Biotech Plans to Progress Development of PDS0301 Immunocytokine in Solid Tumors PRINCETON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today announced it has raised up to $22.55 million in equity funding in a Private Investment in Public Equity (“PIPE”) transacti
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced clinical updates and financial results for H1 2026. Advances in Clinical Programs Pancreatic Cancer Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and d